Herpes zoster vaccine in Korea.
- Author:
Won Suk CHOI
1
Author Information
- Publication Type:Review
- Keywords: Herpes zoster; Neuralgia; Vaccines; Republic of Korea; Review
- MeSH: Adult; Aged; Communicable Diseases; Female; Headache; Herpes Zoster; Herpes Zoster Vaccine; Humans; Korea; Neuralgia; Pregnant Women; Quality of Life; Republic of Korea; Vaccination; Vaccines
- From:Clinical and Experimental Vaccine Research 2013;2(2):92-96
- CountryRepublic of Korea
- Language:English
- Abstract: Herpes zoster and post-herpetic neuralgia deteriorate the quality of life because of severe pain and complications, and cause considerable social and economic burden of disease. In 2012, herpes zoster vaccine was released in Korea. The efficacy of herpes zoster vaccine is known to be 51.3-66.5% among the aged over 60 and 69.8-72.4% among adults between 50 and 59. It is also known that preventive efficacy is maintained for at least 5 years. Although there can be local reactions such as redness, pain and swelling at the site of injection and systemic reaction such as headache and eruption after herpes zoster vaccination, most of the adverse reactions are minor and disappear within days by themselves. As it is a live vaccine, persons with severe immune-suppression and pregnant women should not be vaccinated with the vaccine. Currently, Korean Society of Infectious Diseases recommended for the aged over 60 to be vaccinated with herpes zoster vaccine by subcutaneous route. In this article, clinical aspects and burden of disease of herpes zoster, efficacy and effects of herpes zoster vaccine, and herpes zoster vaccine recommendation by Korean Society of Infectious Diseases are discussed.
